ArticleCellular immunology2012
Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88.
Article in Cellular immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Dysregulation of the TLR4/MYD88 Signaling Pathway in Egyptian Females with Breast Cancer: Implications for Tumor Progression.Molecular biology reports · 2026Article
- Lipopolysaccharide suppresses lung metastasis by activating CD8BMC cancer · 2026Article
- Prognostic and therapeutic implications of tumor-restrictive type III collagen in the breast cancer microenvironment.NPJ breast cancer · 2024Article
- Machine learning-based identification of a cell death-related signature associated with prognosis and immune infiltration in glioma.Journal of cellular and molecular medicine · 2024Article
- MyD88 signaling pathways: role in breast cancer.Frontiers in oncology · 2024Review
- Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence.Surgery today · 2021Article
- Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.Journal of experimental & clinical cancer research : CR · 2018Article
- CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.Oncology letters · 2018Article
- TLR signaling adaptor protein MyD88 in primary sensory neurons contributes to persistent inflammatory and neuropathic pain and neuroinflammation.Scientific reports · 2016Article
- A Multifaceted Role for Myd88-Dependent Signaling in Progression of Murine Mammary Carcinoma.Breast cancer : basic and clinical research · 2016Article
- Type III Collagen Directs Stromal Organization and Limits Metastasis in a Murine Model of Breast Cancer.The American journal of pathology · 2015Article
- Significance of TLR4/MyD88 expression in breast cancer.International journal of clinical and experimental pathology · 2015Article
- TLR4 is a novel determinant of the response to paclitaxel in breast cancer.Molecular cancer therapeutics · 2013Article
- Trial Watch: Toll-like receptor agonists for cancer therapy.Oncoimmunology · 2013Review
- A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro.Cellular immunology · 2013Article
- Suppression of TLR signaling by targeting TIR domain-containing proteins.Current protein & peptide science · 2012Review
- Identification of pathway deregulation--gene expression based analysis of consistent signal transduction.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Previously we reported that lipopolysaccharide (LPS) treatment of murine mammary carcinomas resulted in decreased growth of the tumors. Here we show the decreased growth following LPS treatment was mediated through effects downstream of TLR4 and Myd88. Perhaps more notably, simply reducing TLR4 or Myd88 levels was sufficient to slow tumor growth rates. Moreover, reduced levels of Myd88 correlated with a significant reduction in lung metastasis as well as decreased CCL2 and CCL5 expression. To determine whether inhibiting Myd88 function could also alter tumor growth and chemokine expression we used a Myd88 homodimerization inhibitory peptide. Indeed, inhibiting Myd88 function in four different murine mammary carcinomas as well as the human breast cancer cell line MDA-MB-231 led to decreased growth as well as CCL2 and CCL5 expression. These data imply that Myd88 is important for growth and metastasis of breast cancer, and expression of at least two proinflammatory chemokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.